In virally suppressed adults with HIV and abdominal obesity, tesamorelin showed a trend toward improved neurocognitive performance, but the difference from standard of care was not significant.
In plain wordsIn adults with HIV and abdominal obesity, tesamorelin showed only a trend toward better thinking scores, not clearly different from standard care.
- Peptide
- Tesamorelin
- Outcome
- No significant changeChange in neurocognitive performance at 6 months
- Study
n = 73
- Comparator
- Standard of care
- Analysis
- Primary
- Outcome group
- Cognition and memory · Nervous system and cognition
- Studied dose
- 2 mg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
- Mean change in neurocognitive performance
- 0.146 score
- tesamorelin
- Mean change in neurocognitive performance
- 0.103 score
- standard of care
Source sentences
The tesamorelin group showed a trend toward improved neurocognitive performance after 6 months (mean change, 0.146; 95% CI, -.002 to .294; P = .060) while the SOC group did not (0.103; 95% CI, -.095 to .301; P = .295), but the between-group difference was not significant (P = .673).
3 context sentences(design, population, supporting numbers)
The primary outcome was the change in neurocognitive performance at 6 months, with secondary outcomes including WC, mood, and daily functioning.
This 6-month phase 2 randomized open-label clinical trial compared tesamorelin vs standard of care (SOC) for NCI in people with HIV who were virally suppressed and abdominally obese (elevated waist circumference [WC]).
Seventy-three participants were randomized 3:2 to tesamorelin or SOC (2 mg subcutaneously daily).